0KBS Stock Overview
Engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €52.25 |
| 52 Week High | €54.80 |
| 52 Week Low | €43.92 |
| Beta | 0.40 |
| 11 Month Change | -2.52% |
| 3 Month Change | -0.95% |
| 1 Year Change | 18.08% |
| 33 Year Change | -6.01% |
| 5 Year Change | 42.22% |
| Change since IPO | 704.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0KBS | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 5.3% | 5.0% | 2.2% |
| 1Y | 18.1% | 2.5% | 8.8% |
Return vs Industry: 0KBS exceeded the UK Pharmaceuticals industry which returned 2.5% over the past year.
Return vs Market: 0KBS exceeded the UK Market which returned 8.8% over the past year.
Price Volatility
| 0KBS volatility | |
|---|---|
| 0KBS Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0KBS has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0KBS's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 4,455 | Rob Koremans | www.recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary
| 0KBS fundamental statistics | |
|---|---|
| Market cap | €10.68b |
| Earnings (TTM) | €423.12m |
| Revenue (TTM) | €2.27b |
25.3x
P/E Ratio4.7x
P/S RatioIs 0KBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0KBS income statement (TTM) | |
|---|---|
| Revenue | €2.27b |
| Cost of Revenue | €666.44m |
| Gross Profit | €1.60b |
| Other Expenses | €1.18b |
| Earnings | €423.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.07 |
| Gross Margin | 70.63% |
| Net Profit Margin | 18.65% |
| Debt/Equity Ratio | 81.6% |
How did 0KBS perform over the long term?
See historical performance and comparison